Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

被引：0
|
作者：
Chunxia Qiao
Meiyun Hu
Leiming Guo
Ming Lv
Zhou Lin
Jing Geng
Xiaoling Lang
Xinying Li
Yan Li
Yuanfang Ma
Jiannan Feng
Beifen Shen
机构：
[1] Institute of Basic Medical Sciences,Department of Immunology
[2] Henan University,Laboratory of Cellular and Molecular Immunology, Institute of Immunology
来源：
BMC Immunology | / 13卷
关键词：
TRAIL; Death receptor 5; Monoclonal antibody; Apoptosis; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
    Qiao, Chunxia
    Hu, Meiyun
    Guo, Leiming
    Lv, Ming
    Lin, Zhou
    Geng, Jing
    Lang, Xiaoling
    Li, Xinying
    Li, Yan
    Ma, Yuanfang
    Feng, Jiannan
    Shen, Beifen
    BMC IMMUNOLOGY, 2012, 13
  • [2] Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
    Forero-Torres, Andres
    Shah, Jatin
    Wood, Tina
    Posey, James
    Carlisle, Ronda
    Copigneaux, Catherine
    Luo, Feng
    Wojtowicz-Praga, Slawomir
    Percent, Ivor
    Saleh, Mansoor
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (01) : 13 - 19
  • [3] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
    C Adams
    K Totpal
    D Lawrence
    S Marsters
    R Pitti
    S Yee
    S Ross
    L Deforge
    H Koeppen
    M Sagolla
    D Compaan
    H Lowman
    S Hymowitz
    A Ashkenazi
    Cell Death & Differentiation, 2008, 15 : 751 - 761
  • [4] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
    Adams, C.
    Totpal, K.
    Lawrence, D.
    Marsters, S.
    Pitti, R.
    Yee, S.
    Ross, S.
    Deforge, L.
    Koeppen, H.
    Sagolla, M.
    Compaan, D.
    Lowman, H.
    Hymowitz, S.
    Ashkenazi, A.
    CELL DEATH AND DIFFERENTIATION, 2008, 15 (04): : 751 - 761
  • [5] Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain–FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study
    Hongyi Yang
    Yuhua Song
    Journal of Molecular Modeling, 2016, 22
  • [6] Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
    Straughn, JM
    Oliver, PG
    Zhou, T
    Wang, WQ
    Alvarez, RD
    Grizzle, WE
    Buchsbaum, DJ
    GYNECOLOGIC ONCOLOGY, 2006, 101 (01) : 46 - 54
  • [7] Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study
    Yang, Hongyi
    Song, Yuhua
    JOURNAL OF MOLECULAR MODELING, 2016, 22 (04)
  • [8] An agonistic anti-human DR5 antibody in treatment of autoimmune disease.
    Liu, WM
    Zhao, LM
    Wang, Z
    Ichikawa, K
    Chatham, W
    Szalai, A
    Carter, RH
    Kimberly, RP
    Zhou, T
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S370 - S370
  • [9] Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists
    Li, Bing
    Russell, Stephen J.
    Compaan, Deanne M.
    Totpal, Klara
    Marsters, Scot A.
    Ashkenazi, Avi
    Cochran, Andrea G.
    Hymowitz, Sarah G.
    Sidhu, Sachdev S.
    JOURNAL OF MOLECULAR BIOLOGY, 2006, 361 (03) : 522 - 536
  • [10] Extensive regions of the FADD death domain are required for binding to the TRAIL receptor DR5
    L R Thomas
    L M Bender
    M J Morgan
    A Thorburn
    Cell Death & Differentiation, 2006, 13 : 160 - 162
12345